Literature DB >> 6226726

Isotretinoin treatment of acne and related disorders: an update.

A R Shalita, W J Cunningham, J J Leyden, P E Pochi, J S Strauss.   

Abstract

In the one year since isotretinoin has been available in the United States for the treatment of severe, recalcitrant, nodulocystic acne, there has been extensive clinical verification of the reports of its dramatic efficacy in the treatment of this troublesome disease. Proper selection of patients, as well as treatment with adequate doses of drug for 3 to 5 months, will most often result in significant clinical improvement or total clearing. Although dosages of less than 1 mg/kg/day may produce a nearly equivalent degree of improvement with somewhat fewer or less severe side effects, the recommended daily dose remains 1 mg/kg/day because lower dosages are associated with more frequent relapses. In severe cases, the daily dosage may be increased to 2 mg/kg/day. Teratogenicity, elevation of serum triglycerides, liver function abnormalities, pancreatitis, and pseudotumor cerebri may all be associated with isotretinoin therapy and require close monitoring of the patient.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226726     DOI: 10.1016/s0190-9622(83)70176-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  19 in total

Review 1.  Pathogenesis, clinical features and management of hidradenitis suppurativa.

Authors:  R W Parks; T G Parks
Journal:  Ann R Coll Surg Engl       Date:  1997-03       Impact factor: 1.891

2.  Oral retinoids.

Authors:  N J Lowe
Journal:  West J Med       Date:  1989-12

3.  [Acne vulgaris].

Authors:  M Toscano; J Tousignant; G Panet-Raymond
Journal:  Can Fam Physician       Date:  1992-11       Impact factor: 3.275

4.  Pyogenic granulomas during isotretinoin therapy.

Authors:  Kathleen Armstrong; Miriam Weinstein
Journal:  J Dermatol Case Rep       Date:  2011-03-26

Review 5.  Current views on the aetiology, pathogenesis and treatment of acne vulgaris.

Authors:  L Lever; R Marks
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

6.  [Development of curly hair under systemic therapy with alitretinoin].

Authors:  C Herink; M P Schön; R Mößner
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

7.  Isotretinoin therapy for acne: a population-based study.

Authors:  D J Hogan; L M Strand; P R Lane
Journal:  CMAJ       Date:  1988-01-01       Impact factor: 8.262

Review 8.  The retinoids. A review of their clinical pharmacology and therapeutic use.

Authors:  C E Orfanos; R Ehlert; H Gollnick
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

9.  Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.

Authors:  Raed O Alhusayen; David N Juurlink; Muhammad M Mamdani; Richard L Morrow; Neil H Shear; Colin R Dormuth
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

Review 10.  Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians.

Authors:  Elisabeth Chroni; Alexandra Monastirli; Dionysios Tsambaos
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.